Linda M. Clayton

TL;DR: As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.

TL;DR: Pericardial effusion, right atrial enlargement and septal displacement are echocardiographic abnormalities that reflect the severity of right heart failure and predict adverse outcomes in patients with severe PPH.

TL;DR: The echocardiographic characteristics of participants in this trial; the relationships of echOCardiographic variables to hemodynamic parameters, exercise capacity, and quality of life; and the echoprostenol changes associated with prostacyclin therapy are described.

TL;DR: In a recent prospective randomized study of severely symptomatic patients, treatment with prostacyclin (epoprostenol) produced improvements in hemodynamics, quality of life, and survival as mentioned in this paper.

TL;DR: It is suggested that continuous epoprostenol therapy may have a beneficial effect on the balance between endothelin-1 clearance and release in many patients with primary pulmonary hypertension and may provide one explanation for the salutary effect of epop frostenol in this disease.